PTGX Protagonist Therapeutics
- 32.090
- -0.500-1.53%
Protagonist Therapeutics News
JMP Securities Reiterates Market Outperform on Protagonist Therapeutics, Maintains $45 Price Target
Protagonist Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Protagonist Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
HC Wainwright & Co. : Reiterated Therapeutics (PTGX.US) rating, adjusted from buy to buy rating, target price $38.00.
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
J.P. Morgan Securities: Maintaining the Preservist Therapeutics (PTGX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $42.00 to $45.00.
Protagonist Therapeutics Analyst Ratings
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)
Protagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising Pipeline
Protagonist Therapeutics Earns 'Buy' Rating on Strong Clinical Progress and Strategic Partnerships
Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113
Protagonist Therapeutics Analyst Ratings
Strong Buy Rating for Protagonist Therapeutics on JNJ-2113's Promising Psoriasis Treatment Efficacy and Financial Outlook
JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $37
Protagonist Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Analysis
Price Target
No Data
